StockNews.com initiated coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) in a research report released on Thursday. The firm issued a hold rating on the biotechnology company’s stock.
Other analysts also recently issued reports about the stock. Oppenheimer downgraded shares of BioMarin Pharmaceutical from an outperform rating to a market perform rating in a report on Wednesday, February 22nd. Citigroup initiated coverage on shares of BioMarin Pharmaceutical in a report on Tuesday, February 21st. They issued a neutral rating and a $116.00 price objective on the stock. Canaccord Genuity Group lowered their price objective on shares of BioMarin Pharmaceutical from $119.00 to $112.00 and set a hold rating on the stock in a report on Tuesday, February 28th. Bank of America boosted their target price on shares of BioMarin Pharmaceutical to $200.00 in a report on Wednesday, January 4th. Finally, Stifel Nicolaus boosted their target price on shares of BioMarin Pharmaceutical from $114.00 to $118.00 and gave the stock a buy rating in a report on Tuesday, February 28th. Eight investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $120.11.
BioMarin Pharmaceutical Price Performance
NASDAQ BMRN opened at $91.67 on Thursday. The company has a quick ratio of 3.15, a current ratio of 4.67 and a debt-to-equity ratio of 0.24. BioMarin Pharmaceutical has a 12-month low of $70.73 and a 12-month high of $117.77. The company has a market capitalization of $17.10 billion, a PE ratio of 123.88 and a beta of 0.39. The firm’s 50 day moving average is $106.01 and its 200-day moving average is $97.62.
Insider Buying and Selling at BioMarin Pharmaceutical
Institutional Investors Weigh In On BioMarin Pharmaceutical
Institutional investors have recently modified their holdings of the business. TCI Wealth Advisors Inc. boosted its position in shares of BioMarin Pharmaceutical by 68.0% in the fourth quarter. TCI Wealth Advisors Inc. now owns 247 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 100 shares during the period. Altshuler Shaham Ltd bought a new stake in BioMarin Pharmaceutical during the third quarter worth about $25,000. ICA Group Wealth Management LLC bought a new stake in BioMarin Pharmaceutical during the fourth quarter worth about $31,000. Grey Fox Wealth Advisors LLC bought a new stake in BioMarin Pharmaceutical during the fourth quarter worth about $31,000. Finally, MayTech Global Investments LLC bought a new stake in BioMarin Pharmaceutical during the fourth quarter worth about $36,000. Institutional investors own 96.26% of the company’s stock.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical, Inc engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M.
- Get a free copy of the StockNews.com research report on BioMarin Pharmaceutical (BMRN)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.